This offers new understanding of how Nrxn3 dysfunction contributes to obesity, suggesting that targeting Nrxn3-dependent pathways in the PVN might lead to innovative treatments for obesity prevention and management. Here, NRXN3 is linked to obesity due to melanocortin 4 receptor deficiency.